Trial Profile
Immunogenicity of a Single Dose of GSK Biologicals' Diphtheria, Tetanus and Acellular Pertussis (dTpa) Booster Vaccine (Boostrix [263855]) in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 06 Feb 2019 Status changed from recruiting to discontinued.
- 04 Jun 2018 Status changed from not yet recruiting to recruiting.
- 17 May 2018 Planned End Date changed from 19 Feb 2019 to 15 Mar 2019.